76 related articles for article (PubMed ID: 21918439)
1. HER2-overexpressing breast cancer: time for the cure with less chemotherapy?
Loi S; de Azambuja E; Pugliano L; Sotiriou C; Piccart MJ
Curr Opin Oncol; 2011 Nov; 23(6):547-58. PubMed ID: 21918439
[TBL] [Abstract][Full Text] [Related]
2. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
3. An overview of HER-targeted therapy with lapatinib in breast cancer.
McArthur H
Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
[TBL] [Abstract][Full Text] [Related]
4. Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials.
Bria E; Carbognin L; Furlanetto J; Pilotto S; Bonomi M; Guarneri V; Vicentini C; Brunelli M; Nortilli R; Pellini F; Sperduti I; Giannarelli D; Pollini GP; Conte P; Tortora G
Cancer Treat Rev; 2014 Aug; 40(7):847-56. PubMed ID: 24877987
[TBL] [Abstract][Full Text] [Related]
5. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
8. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
9. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
10. Updates on therapeutic approaches in HER2-positive disease.
Dickler MN
Clin Adv Hematol Oncol; 2010 Feb; 8(2):105-7. PubMed ID: 20386531
[No Abstract] [Full Text] [Related]
11. Combining molecular targeted therapies: clinical experience.
Pivot X; Bedairia N; Thiery-Vuillemin A; Espie M; Marty M
Anticancer Drugs; 2011 Sep; 22(8):701-10. PubMed ID: 21467916
[TBL] [Abstract][Full Text] [Related]
12. Extended anti-HER2 therapy in early breast cancer: longer beats shorter?
Refae S; Pistilli B; Delaloge S
Curr Opin Oncol; 2016 Nov; 28(6):469-475. PubMed ID: 27606697
[TBL] [Abstract][Full Text] [Related]
13. HER2-targeted therapy for early-stage breast cancer: a comprehensive review.
Brown-Glaberman U; Dayao Z; Royce M
Oncology (Williston Park); 2014 Apr; 28(4):281-9. PubMed ID: 24839797
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for HER2 positive breast cancer.
Incorvati JA; Shah S; Mu Y; Lu J
J Hematol Oncol; 2013 Jun; 6():38. PubMed ID: 23731980
[TBL] [Abstract][Full Text] [Related]
15. Next-generation targeted agents in HER2-positive metastatic breast cancer.
Perez EA
Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
[No Abstract] [Full Text] [Related]
16. Targeting HER2 heterogeneity in early-stage breast cancer.
Pernas S; Tolaney SM
Curr Opin Oncol; 2020 Nov; 32(6):545-554. PubMed ID: 32925204
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.
De Boer R; Beith J; Chirgwin J; Chua S; Colosimo M; Francis P; Green M; Pittman K; White M; Wilcken N; Zdenkowski N; Bell R
Asia Pac J Clin Oncol; 2014 Jun; 10 Suppl S4():15-25. PubMed ID: 24797446
[TBL] [Abstract][Full Text] [Related]
18. Dual HER2 targeting for early breast cancer.
Johnston SR
Lancet Oncol; 2013 Nov; 14(12):1145-6. PubMed ID: 24095298
[No Abstract] [Full Text] [Related]
19. COUNTERPOINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
Pegram MD
Oncology (Williston Park); 2015 Nov; 29(11):797, 801-2. PubMed ID: 26573059
[No Abstract] [Full Text] [Related]
20. Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges.
Alameddine RS; Otrock ZK; Awada A; Shamseddine A
Curr Opin Oncol; 2013 May; 25(3):313-24. PubMed ID: 23518595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
